Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D.B., Wahlund, P.O., Ribel, U., Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin (2012) Pharm Res, 29, pp. 2104-2114
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H.W., Johansen, T., Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) (2012) Diabetes Care, 35, pp. 2464-2471
Ethical principles for medical research involving human subjects (2009) J Indian Med Assoc, 107, pp. 403-405. , Declaration of Helsinki
Guideline for good clinical practice (2001) J Postgrad Med, 47, pp. 199-203. , ICH Harmonised Tripartite Guideline
Heise, T., Nosek, L., Bottcher, S.G., Hastrup, H., Haahr, H., Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes (2012) Diabetes Obes Metab, 14, pp. 944-950
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., Haahr, H., Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes (2012) Diabetes Obes Metab, 14, pp. 859-864
Cryer, P.E., Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes (2002) Diabetologia, 45, pp. 937-948
Jabbour, S., Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? (2008) Int J Clin Pract, 62, pp. 845-847
